Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx
Objective<p>This study aimed to evaluate the clinical and immunological significance of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies in rheumatoid arthritis (RA), particularly the association of dual antibody positivity with disease severity, systemic manifestations, and therapeutic resistanc...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1852017546488709120 |
|---|---|
| author | Yan Ma (88810) |
| author2 | Chaoyu Gu (22070708) Qianqian Li (386223) Liangjing Lu (4031372) |
| author2_role | author author author |
| author_facet | Yan Ma (88810) Chaoyu Gu (22070708) Qianqian Li (386223) Liangjing Lu (4031372) |
| author_role | author |
| dc.creator.none.fl_str_mv | Yan Ma (88810) Chaoyu Gu (22070708) Qianqian Li (386223) Liangjing Lu (4031372) |
| dc.date.none.fl_str_mv | 2025-08-18T05:26:16Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1661334.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_Dual_vs_isolated_anti-Ro_antibody_positivity_in_rheumatoid_arthritis_xlsx/29929244 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology rheumatoid arthritis (RA) anti-Ro52 antibody anti-Ro60 antibody difficult-to-treat rheumatoid arthritis (D2T-RA) anti-Ro antibody subtyping |
| dc.title.none.fl_str_mv | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Objective<p>This study aimed to evaluate the clinical and immunological significance of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies in rheumatoid arthritis (RA), particularly the association of dual antibody positivity with disease severity, systemic manifestations, and therapeutic resistance.</p>Methods<p>We conducted a cohort study involving 670 RA patients, stratified into four groups according to anti-Ro52 and anti-Ro60 antibody status: Ro52+/Ro60+, Ro52+/Ro60−, Ro52−/Ro60+, and Ro52−/Ro60−. Clinical characteristics, disease activity scores (DAS28-ESR, DAS28-CRP), systemic complications, and treatment responses were compared among groups. Multivariate logistic regression models identified independent predictors of difficult-to-treat RA (D2T-RA).</p>Results<p>Patients with dual Ro52+/Ro60+ positivity exhibited significantly higher disease activity (median DAS28-ESR: 4.97 vs. 4.39, p = 0.002), worse functional status (median HAQ-DI: 0.88 vs. 0.63, p = 0.001), and increased systemic complications, notably interstitial lung disease (OR = 4.14, 95% CI: 1.71–10.68, p = 0.002) and hematologic involvement (OR = 2.50, 95% CI: 1.02–6.19, p = 0.044), compared to antibody-negative patients. Dual antibody positivity independently predicted an increased risk of developing D2T-RA (OR = 4.05, 95% CI: 1.58–11.09, p = 0.004). Conversely, patients with isolated Ro60 positivity exhibited lower IgG levels, fewer systemic complications, and reduced reliance on biological therapies, indicating a less severe disease phenotype.</p>Conclusion<p>Anti-Ro antibody subtyping effectively identifies distinct clinical and immunological RA subgroups. Patients with isolated Ro60 antibody positivity display a relatively less severe clinical profile compared to those with dual antibody positivity, highlighting the importance of specific antibody profiles in guiding personalized clinical management and therapeutic decision-making.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_02edf02ff331fe3c400e602fceaaa461 |
| identifier_str_mv | 10.3389/fimmu.2025.1661334.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29929244 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsxYan Ma (88810)Chaoyu Gu (22070708)Qianqian Li (386223)Liangjing Lu (4031372)Genetic Immunologyrheumatoid arthritis (RA)anti-Ro52 antibodyanti-Ro60 antibodydifficult-to-treat rheumatoid arthritis (D2T-RA)anti-Ro antibody subtypingObjective<p>This study aimed to evaluate the clinical and immunological significance of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies in rheumatoid arthritis (RA), particularly the association of dual antibody positivity with disease severity, systemic manifestations, and therapeutic resistance.</p>Methods<p>We conducted a cohort study involving 670 RA patients, stratified into four groups according to anti-Ro52 and anti-Ro60 antibody status: Ro52+/Ro60+, Ro52+/Ro60−, Ro52−/Ro60+, and Ro52−/Ro60−. Clinical characteristics, disease activity scores (DAS28-ESR, DAS28-CRP), systemic complications, and treatment responses were compared among groups. Multivariate logistic regression models identified independent predictors of difficult-to-treat RA (D2T-RA).</p>Results<p>Patients with dual Ro52+/Ro60+ positivity exhibited significantly higher disease activity (median DAS28-ESR: 4.97 vs. 4.39, p = 0.002), worse functional status (median HAQ-DI: 0.88 vs. 0.63, p = 0.001), and increased systemic complications, notably interstitial lung disease (OR = 4.14, 95% CI: 1.71–10.68, p = 0.002) and hematologic involvement (OR = 2.50, 95% CI: 1.02–6.19, p = 0.044), compared to antibody-negative patients. Dual antibody positivity independently predicted an increased risk of developing D2T-RA (OR = 4.05, 95% CI: 1.58–11.09, p = 0.004). Conversely, patients with isolated Ro60 positivity exhibited lower IgG levels, fewer systemic complications, and reduced reliance on biological therapies, indicating a less severe disease phenotype.</p>Conclusion<p>Anti-Ro antibody subtyping effectively identifies distinct clinical and immunological RA subgroups. Patients with isolated Ro60 antibody positivity display a relatively less severe clinical profile compared to those with dual antibody positivity, highlighting the importance of specific antibody profiles in guiding personalized clinical management and therapeutic decision-making.</p>2025-08-18T05:26:16ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1661334.s001https://figshare.com/articles/dataset/Table_1_Dual_vs_isolated_anti-Ro_antibody_positivity_in_rheumatoid_arthritis_xlsx/29929244CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/299292442025-08-18T05:26:16Z |
| spellingShingle | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx Yan Ma (88810) Genetic Immunology rheumatoid arthritis (RA) anti-Ro52 antibody anti-Ro60 antibody difficult-to-treat rheumatoid arthritis (D2T-RA) anti-Ro antibody subtyping |
| status_str | publishedVersion |
| title | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| title_full | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| title_fullStr | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| title_full_unstemmed | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| title_short | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| title_sort | Table 1_Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis.xlsx |
| topic | Genetic Immunology rheumatoid arthritis (RA) anti-Ro52 antibody anti-Ro60 antibody difficult-to-treat rheumatoid arthritis (D2T-RA) anti-Ro antibody subtyping |